Breast Cancer Index

NOT ANOTHER MINUTE™

When 95% of women with breast cancer are suffering through treatment that doesn’t benefit them, it’s time to say “not another minute.”

SNAPSHOT

95% of women with HR+ breast cancer don’t respond to the standard treatment. Breast Cancer Index (BCI) is a genomic test that’s proven to tell them for sure.

CHALLENGE

Change the conversation in the medical community, and make BCI the standard of care to determine treatment of HR+ breast cancer.

APPROACH

+ Brand & Culture Positioning
+ Messaging Platform Development
+ Visual Identity Refresh
+ Original Photography
+ Web Copy, Design & Development
+ Redesigned Test Report
+ Integrated Marketing & Advertising
+ KOL Influencer Campaign Support

RESULTS

As a result of our work, the test was added as the standard of care according to the American Society of Clinical Oncology (ASCO) Clinical Practice Guideline.

Then in 2020, the company was acquired one full year ahead of schedule for $230 million, after a 2019 valuation of just $29 million.

“These guys just get it…they helped a $29MM company exit at a $230MM valuation in just 18 months, in the middle of a global pandemic, and a year ahead of schedule. Each time we asked, they delivered.”

— Matt Seargent, Chief Commercial Officer

MEDIA COVERAGE

Katie Couric on YouTube

“Katie Couric's cancer journey from being a caregiver, to advocate, to patient has inspired her to learn about and raise awareness for cancer research for more than two decades.

Katie was thrilled to speak with breast oncologist and Chief Patient Experience Officer at Smilow Cancer Hospital Dr. Tara Sanft and one of her patients, Clara, about a breast cancer gene test, Breast Cancer Index, that can detect a patient's risk of recurrence.”